Our results indicated that patients with high CD247 expression (score 2 and 3) had a more favorable prognosis of survival (Figure 6D), suggesting that CD247 may be a target for tumor immunity in HNSCC and that drugs targeting CD247 could be a potential therapeutic strategy. This evidence concerns the gene CD247 and head and neck squamous cell carcinoma.